Vikram Kaithwas

Deputy Manager at BioGenomics Limited [Ex-Biocon Biologics], [Ex-DRL], [Ex-Wockhardt]

Role: Deputy Manager at Biogenomics
Location: Thane, IN
LinkedIn followers: 500 followers

OperationsView LinkedIn profile

About Vikram Kaithwas

Motivated and result driven scientist with 10 years of progressive experience in R&D with…

Experience

Deputy Manager
Biogenomics
Nov 2023 — Present · Thane, IN
Formulation process development of Insulin and Insulin analogues, Formulation process development of insulin analogues suspension drug product, Crystallization process optimization for suspension drug product of Insulin analogues, Technology Transfer Insulin analogues suspension drug product and Successfully execution of Clinical and Commercial batches, Process and Formulation Characterization, Regulatory Filling Dossier preparation of drug product section as per regulated market (US and EU) requirement. Extractable and Leachable studies, Container closure evaluation (PFS, Cartridge and Vial), Filter sizing and Validation,

Skills

Stability Ich Guidlines
Pharmaceutics
Lifesciences
Patent Searching
Drug Discovery
Pharmaceutical Industry
Chemistry
Life Sciences
Molecular Biology
Pharmaceutical Research
High-Performance Liquid Chromatography (Hplc)
Analytical Chemistry
Biotechnology
Cell Biology
Abbreviated New Drug Application (Anda)
Quality by Design
Anda
Biochemistry
Regulatory Affairs
Design of Experiments
Chromatography
Scale Up and Post Approval Changes (Supac) in Pharmaceuticals Products
Hplc
Pilot Plant Scale Up Pharmaceuticals Products
Formulation

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@biogenomics.co.in
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Biogenomics

Pharmaceutical Manufacturing · 292 employees · Thane, Maharashtra, India

Biogenomics is a science-driven, vertically integrated pharmaceutical company specializing in treatments for diabetes and oncology. Backed by Oman Investment Authority and guided by a team of distinguished scientists, business leaders, and experts in molecular biology, microbiology, and protein engineering, Biogenomics has in a short span of time has developed a wide portfolio of biosimilars and biotech products. As an industry pioneer, Biogenomics became the first company in India to successfully launch a biosimilar of Insulin Aspart. With a robust pipeline, the company has several additional products awaiting approval. Committed to enhancing patient outcomes globally, Biogenomics has an active clinical development program focused on advancing chemical entities and biologics for the treatment of diabetes, cancer, and other critical therapeutic areas. As a young, fast-growing biopharmaceutical firm, Biogenomics is on a path to delivering excellence in healthcare. Our mission is to enrich lives by providing high-quality, affordable drugs, ensuring patient access to expensive specialty pharmaceuticals and biologic treatments. With two new additional manufacturing facilities coming up in India and Oman, Biogenomics is poised for significant global expansion. Beginning filings in 2025, the company plans to extend its reach into North America, Europe, and other key markets, further solidifying its international presence.

biogenomics.co.in

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.